DRUG SAFETY

作者Hadir Rostom; Mohamed A. Elhawary; Mayada Alkhakany; Manal M. Younus; Thamir Alshammari; Felipe Villalobos; Omar Aimer

作者单位1. ISoP MENA Chapter Founding Group, Cairo, Egypt; 2. Faculty of Pharmacy, MSA University, 6th of October City, Egypt; 3. International Society of Pharmacovigilance, ISoP Secretariat Ltd, London, UK; 4. Medical Affairs, SAJA Pharmaceuticals Co., Ltd, Jeddah, Saudi Arabia; 5. Seven D Consultancy, Dubai, UAE; 6. Iraqi Pharmacovigilance Centre, Ministry of Health, Baghdad, Iraq; 7. Department of Pharmacy Practice, College of Pharmacy, Jazan University, Jazan, Saudi Arabia; 8. Pharmacy Practice Research Unit, College of Pharmacy, Jazan University, Jazan, Saudi Arabia; 9. Fundació Institut Universitari per a la Recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain; 10. InnoVigilance, Laval, Canada

作者Sikander Ailawadhi; Elcin Omercikoglu; Aneel Paulus; Ricardo D. Parrondo; Asher A. Chanan-Khan

作者单位1. Division of Hematology-Oncology, Mayo Clinic, Jacksonville, USA; 2. Department of Cancer Biology, Mayo Clinic, Jacksonville, USA

作者Valérie Haine; Tene-Alima Essoh; Caroline Perrin Franck; Miloje Savic

作者单位1. GSK, Wavre, Belgium; 2. Agence de Médecine Préventive Afrique (AMP Afrique), Abidjan, Côte d’Ivoire; 3. Department of Radiology and Medical Informatics, Faculty of Medicine, University of Geneva, Geneva, Switzerland

作者Miyuki Hsing-Chun Hsieh; Zoe Chi-Jui Chang; Chih-Wan Lin; Brian Meng-Hsun Li; Edward Chia-Cheng Lai; Wan-Ting Huang

作者单位1. School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan City, Taiwan; 2. Population Health Data Center, National Cheng Kung University, Tainan City, Taiwan; 3. Department of Pharmacy, Linkou Chang Gung Memorial Hospital, Taoyuan City, Taiwan; 4. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, USA; 5. Global Health Program, College of Public Health, National Taiwan University, Taipei City, Taiwan; 6. National Taiwan University Children’s Hospital, Taipei City, Taiwan

作者Wei Kang; Bowie P. Y. Lam; Rinko Tsz Lam Lau; Silvia T. H. Li; Kangrui Wu; Yue Wei; Yu Yang; Kyung Jin Lee; Caige Huang; Vincent K. C. Yan; Hei Hang Edmund Yiu; Shing Fung Lee; Aya El Helali; Victor H. F. Lee; Stephen L. Chan; Rina Y. M. Hui; Ka On Lam; Esther W. Chan

作者单位1. School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China; 2. Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, China; 3. Institute of Health Economics and Policy, Tianjin University, Tianjin, China; 4. Schulich School of Medicine and Dentistry, Western University, London, Canada; 5. Institute of Clinical Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 6. Department of Radiation Oncology, National University Cancer Institute, National University Hospital, Singapore, Singapore; 7. Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; 8. Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; 9. Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China; 10. State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong SAR, China; 11. Centre of Cancer Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; 12. Accident and Emergency Department, Queen Mary Hospital, Pok Fu Lam, China; 13. Shenzhen Institute of Research and Innovation, The University of Hong Kong, Shenzhen, China

作者Tarek A. Hammad; Justine Rochon

作者单位1. Medical Safety of Marketed Products Development, Plasma-Derived Therapies, Devices, and Vaccines, Patient Safety and Pharmacovigilance, Takeda Development Center Americas, Inc., Cambridge, USA; 2. R&D Data and Quantitative Sciences, Takeda Development Center Americas, Inc., Cambridge, USA

作者Dana Ludwig; Michelle Wang; James Buchanan; Trang Trinh

作者单位1. Bakar Computational Health Sciences Institute, University of California at San Francisco, San Francisco, USA; 2. Covilance, LLC, Belmont, USA; 3. Clinical Pharmacy, University of California at San Francisco, San Francisco, USA; 4. Pharmacotherapeutics & Clinical Research, University of South Florida Taneja College of Pharmacy, Tampa, USA

作者Sigal Kaplan; Julie de Nascimento; Andrea Contini

作者单位1. Epidemiology, Teva Pharmaceutical Industries Ltd., Netanya, Israel; 2. IQVIA, Real World Data, Paris, France

作者Mohamed A. Elhawary; Brian Edwards; Hadir Rostom; Shanthi N. Pal; Viola Macolic Sarinic; Priya Bahri; Deirdre McCarthy; Victoria Prudence Nambasa; Linda Härmark; Andrew Bate; Rebecca Chandler; Marco Tuccori; Fawaz Alharbi; Mohammed Fouda; Comfort Ogar; Jürgen Beckmann; Jayesh Pandit; Mayada Alkhakany; Christina Saad; Manal M. Younus; Ivor Ralph Edwards; Omar Aimer

作者单位1. Egyptian Ministry of Health and Population (General Secretary of ISoP Egypt Chapter), Cairo, Egypt; 2. Faculty of Pharmacy, Ain Shams University, Cairo, Egypt; 3. International Society of Pharmacovigilance, ISoP Secretariat Ltd, London, UK; 4. Husoteria Consultancy Ltd, London, UK; 5. International Society of Pharmacovigilance-Egypt Chapter, Cairo, Egypt; 6. Faculty of Pharmacy, MSA University, Giza, Egypt; 7. Regulation and Safety, World Health Organization, Geneva, Switzerland; 8. European Medicines Agency, Amsterdam, The Netherlands; 9. International Society of Pharmacovigilance, Special Interest Group on Medicinal Product Risk Communication, Geneva, Switzerland; 10. Gates Foundation, Seattle, USA; 11. African Union Development Agency-NEPAD, Johannesburg, South Africa; 12. Drug Safety Research Unit, Southampton, UK; 13. Global Safety, GSK, Middlesex, UK; 14. Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK; 15. Coalition for Epidemic Preparedness Innovations, Oslo, Norway; 16. Section of Pharmacology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy; 17. Regional Centre of Pharmacovigilance-Veneto Region, Verona, Italy; 18. Saudi Food and Drug Authority, Riyadh, Saudi Arabia; 19. United States Pharmacopeia, Rockville, USA; 20. Berlin, Germany; 21. International Society of Pharmacovigilance Africa Chapter, Nairobi, Kenya; 22. Bayer Healthcare, Nairobi, Kenya; 23. International Society of Pharmacovigilance Patient Engagement Special Interest Group, London, UK; 24. Seven D Consultancy, Dubai, UAE; 25. Bayer Pharmaceuticals Inc., Cairo, Egypt; 26. International Society of Pharmacovigilance Middle East Chapter, Baghdad, Iraq; 27. Iraqi Pharmacovigilance Centre, Ministry of Health, Baghdad, Iraq; 28. Gothenburg, Sweden; 29. InnoVigilance, Laval, Canada

作者Anja Jungo; Kanchan Dongre; Delia Halbeisen; Tobias Schneider; Sibylle Chettata; Niklaus Gygli; Murat Bilici; Christoph R. Meier; Anne B. Leuppi-Taegtmeyer

作者单位1. Department of Pharmaceutical Science, University of Basel, Basel, Switzerland; 2. Department of Patient Safety, Medical Directorate, University Hospital Basel, Basel, Switzerland; 3. Department of Clinical Research, University of Basel, Basel, Switzerland; 4. Hospital Pharmacy, University Hospital Basel, Basel, Switzerland; 5. Clinic for Anaesthesia, Intermediate Care, Prehospital Emergency Medicine and Pain Therapy, University Hospital Basel, Basel, Switzerland; 6. Department of Nursing, Medical Directorate, University Hospital Basel, Basel, Switzerland; 7. Department of Quality Management, Medical Directorate, University Hospital Basel, Basel, Switzerland